IJW

Docket No. T2315-907327US02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Laszlo Prokai	:	
Serial No.:	10/801,695	:	Art Unit:
Filed:	March 17, 2004	:	
For:	Antagonists of RF-Amide Neuropeptides	:	Examiner:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with Applicants duty of disclosure, the following information is submitted for consideration by the U.S. Patent and Trademark Office in connection with the above-identified application.

The references listed on the attached Form PTO-1449 were cited in an international search report, and their relevance is indicated therein. The search report was mailed July 14, 2004, from the International Search Authority/United States and a copy is attached herewith.

This statement is filed after three (3) months of the filing date of this application, and after the mailing of the first office action, but prior to the mailing of the Notice of Allowance.

The application relies, under 35 USC §120, on the earlier filing date of prior U.S. Application Serial No. 10/109,000, filed March 29, 2002.

It is respectfully requested that the Examiner fully consider each of the documents, initial the enclosed Form PTO-1449 in the appropriate place to indicate that the document has been considered, and return a copy of the initialed form to the undersigned in accordance with MPEP Section 609.

Respectfully submitted,

MILES & STOCKBRIDGE



Dennis P. Clarke
Registration No. 22,549

Date: September 2, 2004

Customer No. 000181

1751 Pinnacle Drive
Suite 500
McLean, Virginia 22102-3833
Telephone: (703) 903-9000
Facsimile: (703) 610-8686



PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER 10/801,695
	APPLICANT Laszlo Prokai	
	FILING DATE March 17, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	D.H. Malin et al., "Subcutaneous injection of an analog of neuropeptid FF prevents naloxone-precipitated morphine abstinence syndrome", Drug and Alcohol Dependence 40 (1995), pp. 37-42
	A.M. Kawasaki et al., "Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10", International Journal of Peptide & Protein Research, 42, 1993, pp. 411-419
	Ambo et al., "ORLI receptor affinity & Biol. activity", J. Tohoku Phar. Univ., 47, pp. 101-107 (2000), also cited as HCAPLUS DN 136:217029
	L. Prokai et al., "Combinatorial Lead Optimization of a Neuropeptide FF Antagonists", J. Med. Chem., 2001, 44, pp. 1623-1626
	P.P.-C. Tan et al., "Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs", Peptides, 20 (1999) pp 1211-1217
	S.N. Kulkarni et al., "The use of the message-address concept in the design of potential antagonists based on dynorphin A", Chem., Structure and Biol., Proceedings of Am. Peptide Symposium, 14th, Columbia, OH, June 18-23, 1995/96, pp. 655-656
	B. Capuano et al., "Synthesis and preliminary pharmacological evaluation of 4'-arylmethyl analogues of clozapine", Australian J. of Chemistry (2002). 55(9), pp. 565-576
	D. Proske et al., "A Y2 Receptor Mimetic Aptamer Director against Neuropeptide Y", J. Biol. Chemistry, Vol. 277, No. 13, March 29, 2002, pp. 11416-11422

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	